NBIXNeurocrine Biosciences, Inc.
Price
-1.9%1YEnd-of-day closes, not the intraday tick.
A rare clean sweep: double-check what the checks can't see
Quality strong, no red flags, undemanding price, growing in the filings, the market undecided.
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders.
In the company’s own words · 10-K filed Feb 11, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Neurocrine Biosciences, Inc. (NBIX) reported revenue of $959M in Q2 2026 (quarter ended Jun 30, 2026), up 39% from the same quarter a year earlier. That came with a gross margin of 98% and net income of $144M (15% of revenue). For the full year FY2025, revenue was $2.86B (+21% year on year) and net income $479M. Its largest product in Q1 2025 (quarter ended Mar 31, 2025) was Collaboration at $8.9M, 57% of the disclosed total, ahead of Royalty at 43%. The next results filing is expected around Oct 27, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 28, 2026On September 28, 2026, the Board of Directors (the “Board”) of Neurocrine Biosciences, Inc. (the “Company”) appointed Eiry W. Roberts, M.D., to succeed Sanjay Keswani, M.D., as the Company’s Chief Medical Officer, effective September 28, 2026 (the “Transition Date”)Director or officer change · Form 8-K
- Jul 31, 2026“Closing Date”), Neurocrine Biosciences, Inc. (“Neurocrine” or the “Company”) completed the previously announced acquisition (the “Acquisition” or “Transaction”) of Soleno.Material event (exhibits only) · press release
- May 28, 2026, Neurocrine Biosciences, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) at which the Company’s stockholders approved an amendment of the Company’s 2025 Equity Incentive Plan (the “Amended 2025 Plan”)Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q1 2025 · $15.6MThe company’s own SEC segment disclosure.
- Collaboration$8.9M57%
- Royalty$6.7M43%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #6 of 41 by RyuScore